

TECHNICAL SPECIFICATIONS


Drug / Excipient		Delivery System	
Drug	Sirolimus	Delivery System	RX stent delivery system
Drug Dose	1.12 µg/mm ²	Nominal Pressure	8 bar
Drug Carrier	Phospholipid based excipient	Rated Burst Pressure	14 bar*
Stent		Guidewire compatibility (max.)	0.014"
Stent Material	L605 Cobalt Chromium Alloy	Guiding Catheter Compatibility	5F
Strut Thickness	73 µm	Crossing Profile**	0.038"
Strut Width	80 µm (hinge)-120 µm (strut)	Tip Entry Profile	0.016"

* Do not exceed RBP

** Reference Diameter of 3.00 mm

ORDERING INFORMATION

Stent Dia (mm)	Stent Length (mm)								
	08	12	16	20	24	28	32	36	40
2.25	EFO22508	EFO22512	EFO22516	EFO22520	EFO22524	EFO22528	EFO22532	EFO22536	EFO22540
2.50	EFO25008	EFO25012	EFO25016	EFO25020	EFO25024	EFO25028	EFO25032	EFO25036	EFO25040
2.75	EFO27508	EFO27512	EFO27516	EFO27520	EFO27524	EFO27528	EFO27532	EFO27536	EFO27540
3.00	EFO30008	EFO30012	EFO30016	EFO30020	EFO30024	EFO30028	EFO30032	EFO30036	EFO30040
3.50	EFO35008	EFO35012	EFO35016	EFO35020	EFO35024	EFO35028	EFO35032	EFO35036	EFO35040
4.00	EFO40008	EFO40012	EFO40016	EFO40020	EFO40024	EFO40028	EFO40032	EFO40036	EFO40040



*The above diagram is just an illustration of the product.

Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.

CE 1434



CB.BA.FO.BRO.ver.1.0.21-02

Concept Medical

f in /conceptmedical

✉ info@conceptmedical.com

🌐 www.conceptmedical.com

Concept Medical

FOCUS NP

SIROLIMUS BASED NANO CARRIER ELUTING STENT SYSTEM

NON-POLYMER


FOCUS NP DEALS WITH HARD FACTS

HEALING DELAYED

ACUTE / SUB ACUTE / LATE THROMBOSIS

RE-STENOSIS FOCAL / EDGE

DAPT RELATED ISSUES



ABLUMINAL COATING

Drug is coated on the abluminal side only
Leading to unidirectional drug release and less systemic exposure of drug which leads to faster healing



FUSION COATING

(Drug is coated on stent as well as exposed parts of balloon and coated 0.5mm additional on the proximal and distal end of the stent)
Helps to address the entire diseased area of lesion and address the focal restenosis and edge restenosis



POLYMER FREE NANO CARRIER DRUG DELIVERY MATRIX


Designed for acute as well as sustained drug transfer in arterial wall - leading to less chronic inflammation and improved vascular healing




POLYMER FREE COATING

Proposed the shorter DAPT which helps to reduce bleeding risk in patients with high bleeding risk.


MECHANISM OF ACTION




Step 1: Burst drug release from stent and parts of balloon at the time of stent deployment
45 Second inflation holding time recommended




Step 3: Longer duration Drug release from stent



Step 2: Drug release from stent and parts of balloon upon expansion




Step 4: Converts to BMS @ 40 days





+



Sirolimus sub-micron particle



Sirolimus encapsulated in phospholipid drug carrier

Balloon Surface
Stent Surface

ADVANTAGE OF NANOACTIVE TECHNOLOGY

- Better in-tissue bioavailability of drug
- Effective drug transfer to the deepest layer of the vessel
- Reduces drug dose
- Protect drug by encapsulation – reduced in-transit drug loss